• About Us
  • About Neurocrine
  • Leadership Team
    • Management Team
    • Board of Directors
  • Culture & Values
    • Patient Access & Pricing
    • Diversity & Equality
  • News & Events
  • Webcasts & Presentations
  • Contact Us
• Patients & Families
  • Overview
  • Tardive Dyskinesia
  • Parkinson’s Disease
  • Congenital Adrenal Hyperplasia
  • Chorea in Huntington Disease
  • Epilepsy
  • Women’s Health
  • Psychiatric Disorders
• Products
• Pipeline
  • OVERVIEW
  • Congenital Adrenal Hyperplasia
    • Crinecerfont
      • Clinical Trials
  • Chorea in Huntington Disease
    • Valbenazine
      • Clinical Trials
  • Women’s Health
    • Polycystic Ovary Syndrome
  • Psychiatric Disorders
    • Schizophrenia
      • Luvadaxistat (NBI-1065844/TAK-831)
        • Clinical Trials
    • Major Depressive Disorder (MDD)
      • NBI-1065845 (TAK-653)
    • Anhedonia
      • NBI-1065846 (TAK-041)
  • Epilepsy
    • NBI-827104
      • Clinical Trials
    • NBI-921352 (XEN901)
  • Additional Pipeline Programs
• Careers
  • Overview
  • Culture and Values
  • Benefits
  • Recruitment Agencies
• Investors
  • Press Releases
  • Stock Quote
  • SEC Filings
  • Shareholder Contacts
  • Partners/Collaborators
  • Annual Meeting
  • Online Annual Reports
  • Ownership
  • Email Alerts
  • Corporate Governance
  • Corporate Sustainability
  • Webcasts & Presentations
• Contact Us